David Muller, PhD

Dr. Muller is a serial entrepreneur with a particular interest in ophthalmology. Allotex, Inc, led by Dr. Muller, is pioneering the use of corneal allograft tissue to treat presbyopia, thereby reducing or eliminating the need to wear reading glasses. All people over the age of about 45 will eventually require reading glasses and with the aging population, the market for this product is very large. Prior to founding Allotex, Dr. Muller recognized the potential of a procedure known as corneal cross linking and founded Avedro, Inc. The company successfully obtained FDA approval for the technology in 2016 and now it is available worldwide to treat keratoconus, an orphan indication which is often sight threatening. Earlier in his career, as the founder, Chairman of the Board and CEO of Summit Technology, he led the team that brought the first FDA-approved laser vision correction to the market. David holds an AB from Boston University, a doctorate in physical chemistry from Cornell University and an MBA from The Wharton School of the University of Pennsylvania.